{
    "Trade/Device Name(s)": [
        "ARK Levetiracetam II Assay"
    ],
    "Submitter Information": "ARK Diagnostics, Inc.",
    "510(k) Number": "K232522",
    "Predicate Device Reference 510(k) Number(s)": [
        "K091653"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "ORI"
    ],
    "Summary Letter Date": "January 12, 2024",
    "Summary Letter Received Date": "January 12, 2024",
    "Submission Date": "August 18, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.3350"
    ],
    "Regulation Name(s)": [
        "Diphenylhydantoin test system"
    ],
    "Analyte Class(es)": [
        "tdm"
    ],
    "Analyte(s)": [
        "Levetiracetam"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzer",
        "Beckman Coulter AU680"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay (EIA)"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ARK Levetiracetam II Assay, a homogeneous enzyme immunoassay for quantitative determination of levetiracetam in serum or plasma.",
    "Indications for Use Summary": "Intended for quantitative determination of levetiracetam in human serum or plasma on automated clinical chemistry analyzers as an aid in management of patients treated with levetiracetam.",
    "fda_folder": "Toxicology"
}